Biolidics Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

CEO

Biolidics heeft geen CEO, of we hebben geen gegevens over hen.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Hua Zhu	Executive Chairman	less than a year	geen gegevens	29.9% SGD 4.5m
Lu Chen	President & Executive Director	less than a year	geen gegevens	geen gegevens
Chwee Lim	Founder and Advisor	no data	geen gegevens	0.43% SGD 66.0k
Tan Jin	Co-Founder and Technical Advisor	no data	geen gegevens	geen gegevens
Lau Wei Kian	Financial Controller	less than a year	geen gegevens	geen gegevens
Ali Bhagat	Technical Director	no data	geen gegevens	geen gegevens
Hafiza Alwi Nor	Company Secretary	2.3yrs	geen gegevens	geen gegevens

0.6yrs

Gemiddelde duur

Ervaren management: Het managementteam van 8YY wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.6 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Hua Zhu	Executive Chairman	less than a year	geen gegevens	29.9% SGD 4.5m
Lu Chen	President & Executive Director	less than a year	geen gegevens	geen gegevens
Ian David Brown	Non-Executive Independent Director	3.4yrs	geen gegevens	geen gegevens
Li-Ling Ch'ng	Lead Independent Director	1.7yrs	geen gegevens	geen gegevens
Yoke Pheng Liew	Non-Executive Independent Director	less than a year	geen gegevens	geen gegevens

1.0yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 8YY wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1 jaar), wat duidt op een nieuw bestuur.

Biolidics Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Biolidics Limited Announces Resignation of Gavin Mark Mcintyre as Lead Independent Director and Member of the AC and RR

Biolidics Limited Announces the Resignation of Siu Yeung Sau as Financial Controller

Biolidics Limited, Annual General Meeting, Apr 29, 2024

Biolidics Limited, Annual General Meeting, Apr 29, 2024

Biolidics Limited Announces the Redesignation of Zhu Hua from Non-Executive Non-Independent Director to Executive Director

High number of new and inexperienced directors

Recent updates

Third quarter 2024 earnings released: S$0.001 loss per share (vs S$0.001 loss in 3Q 2023)

Biolidics Limited (Catalist:8YY) completed the acquisition of Shenzhen Xiaozhao Network Technology Co., Ltd from Dreamsgame Inc.

New major risk - Shareholder dilution

Second quarter 2024 earnings released: S$0.001 loss per share (vs S$0.001 loss in 2Q 2023)

Biolidics Limited Announces Resignation of Gavin Mark Mcintyre as Lead Independent Director and Member of the AC and RR

Biolidics Limited Announces the Resignation of Siu Yeung Sau as Financial Controller

First quarter 2024 earnings released: S$0.001 loss per share (vs S$0.001 loss in 1Q 2023)

New major risk - Revenue size

Biolidics Limited, Annual General Meeting, Apr 29, 2024

Biolidics Limited, Annual General Meeting, Apr 29, 2024

Biolidics Limited Announces the Redesignation of Zhu Hua from Non-Executive Non-Independent Director to Executive Director

New minor risk - Insider selling

Full year 2023 earnings released: S$0.004 loss per share (vs S$0.033 loss in FY 2022)

Biolidics Limited has completed a Follow-on Equity Offering in the amount of SGD 1.0043 million.

Biolidics Limited has completed a Follow-on Equity Offering in the amount of SGD 1.0043 million.

High number of new and inexperienced directors

Biolidics Limited Appoints Zhu Hua as A Non-Executive Non-Independent Director

Biolidics Limited Announces Board Changes

Biolidics Limited has filed a Follow-on Equity Offering in the amount of SGD 1.17215 million.

Third quarter 2023 earnings released: S$0.001 loss per share (vs S$0.003 loss in 3Q 2022)

New major risk - Share price stability

Biolidics Limited Announces Resignation of Gavin Mark Mcintyre as Independent Director and Non-Executive Independent Chairman, Chairman of the Ac and Member of the NC and the RC

Second quarter 2023 earnings released: S$0.001 loss per share (vs S$0.004 loss in 2Q 2022)

First quarter 2023 earnings released: S$0.001 loss per share (vs S$0.004 loss in 1Q 2022)

Full year 2022 earnings released: S$0.033 loss per share (vs S$0.023 loss in FY 2021)

Biolidics Limited Provides Group Earnings Guidance for the Financial Year Ended 31 December 2022

High number of new and inexperienced directors

Third quarter 2022 earnings released: S$0.003 loss per share (vs S$0.006 loss in 3Q 2021)

High number of new and inexperienced directors

Biolidics Limited Announces Management Changes

First half 2022 earnings released

Biolidics Limited Announces Company Secretary Changes

Biolidics Limited Ordinary Shares Japan to Be Deleted from OTC Equity

Biolidics Limited Announces Company Secretary Changes, Effective from 24 June 2022

Biolidics Limited Announces Resignation of Leong Man Chun as Chief Scientific Officer

Biolidics Limited Appoints Siu Yeung Sau as Financial Controller

Full year 2021 earnings released: S$0.023 loss per share (vs S$0.018 loss in FY 2020)

Biolidics Limited, Annual General Meeting, Apr 28, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Biolidics Limited Announces Changes to the Composition of the Board of Directors and Board Committees of the Company

High number of new directors

Biolidics Limited Provides Update on Development of the ClearEpi SARS-CoV-2 Neutralising Antibody Rapid Test Kit and Receipt of CE Marking

Director Chee Keong Kong sitting on 3 company boards

Chief Operating Officer Qingyin Wang has left the company

Independent Director has left the company

Independent Director has left the company

Full year 2020 earnings released: S$0.018 loss per share (vs S$0.02 loss in FY 2019)

Biolidics Limited Provides Update on ClearEpi SARS-CoV-2 Antigen Rapid Test Kit

New 90-day low: S$0.28

Full year 2020 earnings released

Biolidics Limited Announces Distribution Agreement with Joysbio (Tianjin) Biotechnology Co, Ltd

New 90-day low: S$0.28

New 90-day low - S$0.28

Earnings released

CEO

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd